Something New Every Day Defining Innovation and Innovativeness in Drug Therapy

被引:17
作者
Aronson, Jeffrey K. [1 ]
机构
[1] Univ Oxford, Dept Primary Hlth Care, Rosemary Rue Bldg,Old Rd Campus, Oxford OX3 7LF, England
关键词
benefit to harm balance; drug therapy; innovation; innovativeness;
D O I
10.1097/01.JAC.0000304100.38120.b2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The word "innovation" comes from the Latin noun innovatio, derived from the verb innovare, to introduce [something] new. It can refer either to the act of introducing something new or to the thing itself that is introduced. In terms of commerce, it is defined in the Oxford English Dictionary as "the action of introducing a new product into the market; a product newly brought on to the market," a definition that illustrates both aspects of the word's meaning. "Innovativeness" is the property of being an innovation. Here I identify several different types of innovativeness in drug therapy, including structural, pharmacological or pharmacodynamic, pharmaceutical, and pharmacokinetic innovativeness, and I stress the over-riding importance of clinical innovativeness, which should result in a better benefit to harm balance at an affordable cost.
引用
收藏
页码:65 / 68
页数:4
相关论文
共 12 条
  • [1] Apolone G., 2007, J AMBULATORY CARE MA, V31, P52
  • [2] NICE's cost effectiveness threshold - How high should it be?
    Appleby, John
    Devlin, Nancy
    Parkin, David
    [J]. BRITISH MEDICAL JOURNAL, 2007, 335 (7616): : 358 - 359
  • [3] Drug development: more science, more education
    Aronson, JK
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (04) : 377 - 378
  • [4] Medicines regulation and clinical pharmacology
    Baber, NS
    Ritter, JM
    Aronson, JK
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (06) : 569 - 570
  • [5] Macro trends in pharmaceutical innovation
    Cohen, FJ
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (01) : 78 - 84
  • [6] *DEP TRAD IND, 2002, INV INN STRAT SCI EN
  • [7] Erice Group, 2007, BRIT J CLIN PHARM
  • [8] FDA, 2004, CHALL OPP CRIT PATH
  • [9] Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003
    Motola, D
    De Ponti, F
    Rossi, P
    Martini, N
    Montanaro, N
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (04) : 475 - 478
  • [10] An update on the first decade of the European centralized procedure: how many innovative drugs?
    Motola, Domenico
    De Ponti, Fabrizio
    Poluzzi, Elisabetta
    Martini, Nello
    Rossi, Pasqualino
    Silvani, Maria Chiara
    Vaccheri, Alberto
    Montanaro, Nicola
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (05) : 610 - 616